246 related articles for article (PubMed ID: 28509416)
1. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.
Cardoso CC; Auat M; Santos-Pirath IM; Rudolf-Oliveira RCM; da Silva JP; Lange BG; Siegel D; de Moraes ACR; Del Moral JAG; Santos-Silva MC
Cytometry B Clin Cytom; 2018 May; 94(3):451-458. PubMed ID: 28509416
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma.
Espasa A; Tapia G; Vergara S; Raya M; Juncà J; Sorigue M
Scand J Clin Lab Invest; 2021 Sep; 81(5):413-417. PubMed ID: 34057378
[TBL] [Abstract][Full Text] [Related]
3. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
4. Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.
Wang W; Li Y; Rivera Rivera X; Zhao L; Mei D; Hu W; Jiang B
BMC Cancer; 2021 Sep; 21(1):1011. PubMed ID: 34503477
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.
Fu H; Jin C; Zhu Q; Liu T; Ke B; Li A; Zhang T
Am J Transl Res; 2019; 11(2):1092-1101. PubMed ID: 30899409
[TBL] [Abstract][Full Text] [Related]
6. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
Schniederjan SD; Li S; Saxe DF; Lechowicz MJ; Lee KL; Terry PD; Mann KP
Am J Clin Pathol; 2010 May; 133(5):718-26. PubMed ID: 20395518
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children].
Yang WP; Zhu CD; Gong LP; Lü BB; Zou Y; Zhong HS; Xiao Q; Wu Y; Xu HY; Zeng ST; Huang H
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):759-64. PubMed ID: 20079016
[TBL] [Abstract][Full Text] [Related]
9. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
11. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
[TBL] [Abstract][Full Text] [Related]
14. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
15. Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.
Berker N; Yeğen G; Özlük Y; Doğan Ö
Turk J Haematol; 2023 Aug; 40(3):162-173. PubMed ID: 37519110
[TBL] [Abstract][Full Text] [Related]
16. Immunological subtypes analysis of Uygur diffuse large B-cell lymphoma in Xinjiang and their prognostic significance.
Jia CD; Liang LP; Yang LL; Yue N; Zhao F; Bai JP
J Cancer Res Ther; 2015; 11(4):852-6. PubMed ID: 26881530
[TBL] [Abstract][Full Text] [Related]
17. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
19. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]